Hrt Financial LP Arcus Biosciences, Inc. Transaction History

Hrt Financial LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$14.59 - $18.48 $679,587 - $860,779	46,579 New	46,579 $709,000
Q4 2023 Feb 09, 2024	BUY	$13.43 - $19.63 $1.29 Million - $1.88 Million	95,819 New	95,819 $1.83 Million
Q4 2022 Feb 10, 2023	BUY	$19.7 - $35.71 $2.46 Million - $4.46 Million	124,820 New	124,820 $2.58 Million
Q2 2022 Aug 12, 2022	BUY	$17.23 - $37.73 $597,433 - $1.31 Million	34,674 New	34,674 $878,000
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $304,816 - $482,276	-11,652 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$17.0 - $32.36 $198,084 - $377,058	11,652 New	11,652 $302,000

201

51.2M

288K

138K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $649M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.